 Eloxx Pharmaceuticals, Inc., ELOX a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that enrollment in our Phase 2 clinical trials for ELX-02 in cystic fibrosis have been temporarily paused in response to the COVID-19 pandemic. Public health authorities worldwide have recommended that people at high risk stay at home as much as possible, cancel non-essential doctors visits and avoid unnecessary exposure to people and public spaces. 